204 related articles for article (PubMed ID: 34760694)
21. Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) originating from hepatic progenitor cell: a case report and review of the literature.
Hu J; Yuan R; Huang C; Shao J; Zou S; Wang K
World J Surg Oncol; 2016 Aug; 14(1):218. PubMed ID: 27535234
[TBL] [Abstract][Full Text] [Related]
22. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis.
Zhang Y; Chen S; Li J; Dai W; Qian Y
World J Surg Oncol; 2021 Feb; 19(1):59. PubMed ID: 33618734
[TBL] [Abstract][Full Text] [Related]
23. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Bösmüller H; Pfefferle V; Bittar Z; Scheble V; Horger M; Sipos B; Fend F
Pathol Res Pract; 2018 Aug; 214(8):1136-1141. PubMed ID: 29935812
[TBL] [Abstract][Full Text] [Related]
24. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma.
Jing CY; Fu YP; Huang JL; Zhang MX; Yi Y; Gan W; Xu X; Shen HJ; Lin JJ; Zheng SS; Zhang J; Zhou J; Fan J; Ren ZG; Qiu SJ; Zhang BH
Oncologist; 2018 Dec; 23(12):1482-1493. PubMed ID: 30257891
[TBL] [Abstract][Full Text] [Related]
26. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
[TBL] [Abstract][Full Text] [Related]
27. Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance.
Cao J; Zhang C; Jiang GQ; Jin SJ; Gao ZH; Wang Q; Yu DC; Ke AW; Fan YQ; Li DW; Wang AQ; Bai DS
Mol Med Rep; 2019 Aug; 20(2):1915-1924. PubMed ID: 31257527
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
30. Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data.
Xiong Y; Deng Y; Wang K; Zhou H; Zheng X; Si L; Fu Z
EBioMedicine; 2018 Oct; 36():183-195. PubMed ID: 30243491
[TBL] [Abstract][Full Text] [Related]
31. Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Connell LC; Harding JJ; Shia J; Abou-Alfa GK
Chin Clin Oncol; 2016 Oct; 5(5):66. PubMed ID: 27829279
[TBL] [Abstract][Full Text] [Related]
32. Development of a Prognostic Signature Based on Single-Cell RNA Sequencing Data of Immune Cells in Intrahepatic Cholangiocarcinoma.
Su M; Qiao KY; Xie XL; Zhu XY; Gao FL; Li CJ; Zhao DQ
Front Genet; 2020; 11():615680. PubMed ID: 33613623
[TBL] [Abstract][Full Text] [Related]
33. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
35. Integrating machine learning to construct aberrant alternative splicing event related classifiers to predict prognosis and immunotherapy response in patients with hepatocellular carcinoma.
Liu W; Zhao S; Xu W; Xiang J; Li C; Li J; Ding H; Zhang H; Zhang Y; Huang H; Wang J; Wang T; Zhai B; Pan L
Front Pharmacol; 2022; 13():1019988. PubMed ID: 36263133
[No Abstract] [Full Text] [Related]
36. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
37. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
38. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis.
Li R; Yuan MX; Ma KS; Li XW; Tang CL; Zhang XH; Guo DY; Yan XC
PLoS One; 2014; 9(5):e98612. PubMed ID: 24874413
[TBL] [Abstract][Full Text] [Related]
39. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
40. Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma.
Holzner ML; Tabrizian P; Parvin-Nejad FP; Fei K; Gunasekaran G; Rocha C; Facciuto ME; Florman S; Schwartz ME
Liver Transpl; 2020 Jul; 26(7):888-898. PubMed ID: 32352208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
